Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

OKYO vs ALDX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
OKYO
OKYO Pharma Limited

Biotechnology

HealthcareNASDAQ • GB
Market Cap$66M
5Y Perf.-20.5%
ALDX
Aldeyra Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$104M
5Y Perf.-44.0%

OKYO vs ALDX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
OKYO logoOKYO
ALDX logoALDX
IndustryBiotechnologyBiotechnology
Market Cap$66M$104M
Revenue (TTM)$0.00$0.00
Net Income (TTM)$-5M$-43M
Forward P/E24.7x
Total Debt$0.00$15M
Cash & Equiv.$2M$55M

OKYO vs ALDXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

OKYO
ALDX
StockMay 22May 26Return
OKYO Pharma Limited (OKYO)10079.5-20.5%
Aldeyra Therapeutic… (ALDX)10056.0-44.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: OKYO vs ALDX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALDX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. OKYO Pharma Limited is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
OKYO
OKYO Pharma Limited
The Income Pick

OKYO is the clearest fit if your priority is income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 0.98
  • EPS growth 0.1%
  • -55.0% 10Y total return vs ALDX's -72.1%
Best for: income & stability and growth exposure
ALDX
Aldeyra Therapeutics, Inc.
The Growth Leader

ALDX carries the broadest edge in this set and is the clearest fit for growth and quality.

  • 3.6% revenue growth vs OKYO's -11K%
  • 4.1% margin vs OKYO's -23.9%
  • -55.5% ROA vs OKYO's -128.4%
Best for: growth and quality
See the full category breakdown
CategoryWinnerWhy
GrowthALDX logoALDX3.6% revenue growth vs OKYO's -11K%
Quality / MarginsALDX logoALDX4.1% margin vs OKYO's -23.9%
Stability / SafetyOKYO logoOKYOBeta 0.98 vs ALDX's 1.28
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)OKYO logoOKYO+10.1% vs ALDX's -19.9%
Efficiency (ROA)ALDX logoALDX-55.5% ROA vs OKYO's -128.4%

OKYO vs ALDX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLOKYOLAGGINGALDX

Income & Cash Flow (Last 12 Months)

OKYO leads this category, winning 1 of 1 comparable metric.

OKYO and ALDX operate at a comparable scale, with $0 and $0 in trailing revenue.

MetricOKYO logoOKYOOKYO Pharma Limit…ALDX logoALDXAldeyra Therapeut…
RevenueTrailing 12 months$0$0
EBITDAEarnings before interest/tax-$4M-$45M
Net IncomeAfter-tax profit-$5M-$43M
Free Cash FlowCash after capex-$2M-$40M
Gross MarginGross profit ÷ Revenue
Operating MarginEBIT ÷ Revenue
Net MarginNet income ÷ Revenue
FCF MarginFCF ÷ Revenue
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year+83.3%+48.0%
OKYO leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

OKYO leads this category, winning 1 of 1 comparable metric.
MetricOKYO logoOKYOOKYO Pharma Limit…ALDX logoALDXAldeyra Therapeut…
Market CapShares × price$66M$104M
Enterprise ValueMkt cap + debt − cash$65M$65M
Trailing P/EPrice ÷ TTM EPS-13.58x-1.84x
Forward P/EPrice ÷ next-FY EPS est.24.71x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue
Price / BookPrice ÷ Book value/share1.45x
Price / FCFMarket cap ÷ FCF
OKYO leads this category, winning 1 of 1 comparable metric.

Profitability & Efficiency

OKYO leads this category, winning 3 of 5 comparable metrics.

On the Piotroski fundamental quality scale (0–9), OKYO scores 3/9 vs ALDX's 1/9, reflecting mixed financial health.

MetricOKYO logoOKYOOKYO Pharma Limit…ALDX logoALDXAldeyra Therapeut…
ROE (TTM)Return on equity-87.7%
ROA (TTM)Return on assets-128.4%-55.5%
ROICReturn on invested capital-3.7%
ROCEReturn on capital employed-56.7%
Piotroski ScoreFundamental quality 0–931
Debt / EquityFinancial leverage0.22x
Net DebtTotal debt minus cash-$2M-$39M
Cash & Equiv.Liquid assets$2M$55M
Total DebtShort + long-term debt$0$15M
Interest CoverageEBIT ÷ Interest expense-8.03x-21.72x
OKYO leads this category, winning 3 of 5 comparable metrics.

Total Returns (Dividends Reinvested)

OKYO leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in OKYO five years ago would be worth $4,503 today (with dividends reinvested), compared to $1,437 for ALDX. Over the past 12 months, OKYO leads with a +10.1% total return vs ALDX's -19.9%. The 3-year compound annual growth rate (CAGR) favors OKYO at -8.5% vs ALDX's -45.5% — a key indicator of consistent wealth creation.

MetricOKYO logoOKYOOKYO Pharma Limit…ALDX logoALDXAldeyra Therapeut…
YTD ReturnYear-to-date-26.9%-63.0%
1-Year ReturnPast 12 months+10.1%-19.9%
3-Year ReturnCumulative with dividends-23.5%-83.8%
5-Year ReturnCumulative with dividends-55.0%-85.6%
10-Year ReturnCumulative with dividends-55.0%-72.1%
CAGR (3Y)Annualised 3-year return-8.5%-45.5%
OKYO leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

OKYO leads this category, winning 2 of 2 comparable metrics.

OKYO is the less volatile stock with a 0.98 beta — it tends to amplify market swings less than ALDX's 1.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OKYO currently trades 48.7% from its 52-week high vs ALDX's 28.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricOKYO logoOKYOOKYO Pharma Limit…ALDX logoALDXAldeyra Therapeut…
Beta (5Y)Sensitivity to S&P 5000.98x1.28x
52-Week HighHighest price in past year$3.35$6.18
52-Week LowLowest price in past year$1.32$1.07
% of 52W HighCurrent price vs 52-week peak+48.7%+28.0%
RSI (14)Momentum oscillator 0–10050.242.5
Avg Volume (50D)Average daily shares traded93K3.6M
OKYO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricOKYO logoOKYOOKYO Pharma Limit…ALDX logoALDXAldeyra Therapeut…
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$9.67
# AnalystsCovering analysts19
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

OKYO leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.

Best OverallOKYO Pharma Limited (OKYO)Leads 5 of 6 categories
Loading custom metrics...

OKYO vs ALDX: Frequently Asked Questions

7 questions · data-driven answers · updated daily

01

Is OKYO or ALDX a better buy right now?

Analysts rate Aldeyra Therapeutics, Inc.

(ALDX) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — OKYO or ALDX?

Over the past 5 years, OKYO Pharma Limited (OKYO) delivered a total return of -55.

0%, compared to -85. 6% for Aldeyra Therapeutics, Inc. (ALDX). Over 10 years, the gap is even starker: OKYO returned -55. 0% versus ALDX's -72. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — OKYO or ALDX?

By beta (market sensitivity over 5 years), OKYO Pharma Limited (OKYO) is the lower-risk stock at 0.

98β versus Aldeyra Therapeutics, Inc. 's 1. 28β — meaning ALDX is approximately 30% more volatile than OKYO relative to the S&P 500.

04

Which has better profit margins — OKYO or ALDX?

OKYO Pharma Limited (OKYO) is the more profitable company, earning 0.

0% net margin versus 0. 0% for Aldeyra Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OKYO leads at 0. 0% versus 0. 0% for ALDX. At the gross margin level — before operating expenses — OKYO leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

05

Which pays a better dividend — OKYO or ALDX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

06

Is OKYO or ALDX better for a retirement portfolio?

For long-horizon retirement investors, OKYO Pharma Limited (OKYO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

98)). Both have compounded well over 10 years (OKYO: -55. 0%, ALDX: -72. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

07

What are the main differences between OKYO and ALDX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

OKYO

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALDX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.